Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 ... in the TAVR Market Per a research report, the global TAVR market was valued at $6.3 billion in 2023 and is ...

Over the past few quarters, TAVR sales have been driven by the strong performance of the Edwards SAPIEN 3 Ultra valve in the United States, Europe and Rest of World, the Edwards SAPIEN 3 Ultra ...

Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for ... mitral valve and tricuspid repair devices. Last year it bought a mitral ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Transcatheter Aortic Valve Implantation: Current & Future Devices To date, most clinical experience has been gathered using the Edwards Sapien™ and the CoreValve™ systems, both of which have ...

A National Transcatheter Aortic Valve ... (creatinine > 3.0 mg/dl or preoperative renal replacement). Eligible patients were randomized to receive the second-generation Edwards SAPIEN heart ...

Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker ... company's Partner 3 trial for its TAVR heart valve Sapen ...

In the last reported quarter, the company’s adjusted earnings per share of 67 cents were in line with the Zacks Consensus Estimate. The company’s earnings beat estimates in one of the trailing ...

Edwards Lifesciences Corporation EW is expected to report fourth-quarter 2024 results shortly. See the Zacks Earnings Calendar to stay ahead of market-making news. In the last reported quarter ...